Viromed Medical AG has received funding approval from Germany's Federal Ministry of Research, Technology and Space for research and development projects in cold plasma technology. The certification was granted under the Research Allowance Act and comprises funding in the high six-figure euro range, highlighting the government's recognition of this medical innovation's potential.
The funding focuses on developing innovative medical systems for applying cold atmospheric plasma, including a stationary system called PulmoPlas® designed for integration into ventilation processes. This technology aims to selectively inactivate pathogenic germs in the lower respiratory tract, potentially enabling new therapeutic approaches in intensive care medicine where respiratory infections pose significant challenges. The development addresses a critical need in healthcare settings where conventional treatments sometimes prove insufficient against resistant pathogens.
Additionally, the funding supports the development of ViroCap®, a mobile device for contact-free plasma application to support wound healing. Both projects expand the current state of the art in medical technology and address key challenges in infection control and tissue repair. The application of cold plasma in the lungs represents a particularly novel approach for which no comparable systems currently exist, according to the company's announcement.
The funding underscores Viromed's innovative capabilities and confirms the scientific and technological relevance of its solutions. With this financial support, Viromed is advancing the development of both PulmoPlas® and ViroCap® while strengthening its position in non-pharmacological treatment of infectious diseases. The company, which has been listed on the stock exchange since October 2022, focuses on distributing innovative cold plasma technology through its wholly owned subsidiary Viromed Medical GmbH.
This development matters because it represents progress toward new treatment modalities that could reduce reliance on antibiotics and address drug-resistant infections. The technology's potential application in intensive care units could significantly impact patient outcomes, particularly for those vulnerable to respiratory infections. The mobile wound healing device could also transform outpatient care and chronic wound management. The funding indicates governmental recognition of cold plasma technology's potential to address pressing healthcare challenges, potentially leading to broader adoption and further research investment in this field. More information about the company is available at https://www.viromed-medical-ag.de.
